Physician profile
Geraldei Paul
NPI 1609485945
$4,105.75
in general payments reported to CMS, 2019-2025
17 companies · $854 in 2025
The $854 reported for 2025 was more than what 83% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $106 · 2023: $1,676 · 2024: $1,469 · 2025: $854.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,987 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,987.14 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $934.23 | 2022-2025 | Rexulti, Abilify Mycite, Abilify Maintena |
| Abbvie INC. | $866.26 | 2022-2025 | |
| Alkermes, INC. | $786.51 | 2023-2025 | Aristada, Lybalvi, Aristada Initio |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $434.65 | 2023-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $269.18 | 2024-2025 | Qelbree |
| Teva Pharmaceuticals USA, INC. | $168.13 | 2022-2024 | Uzedy, Austedo Xr, Austedo |
| Axsome Therapeutics, INC. | $121.85 | 2024 | Auvelity |
| Lundbeck LLC | $96.50 | 2023-2024 | Rexulti, Brintellix |
| Sage Therapeutics, LLC | $82.01 | 2024-2025 | Zurzuvae |
| Vertical Pharmaceuticals, LLC | $79.80 | 2023-2024 | Relexxii |
| Corium, LLC | $75.68 | 2023-2025 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $52.86 | 2024-2025 | Cobenfy |
| Avion Pharmaceuticals | $36.64 | 2023 | Methylphenidate Hydrochloride |
| Janssen Pharmaceuticals, INC | $31.43 | 2023-2024 | Spravato, Invega Sustenna |
| Neurocrine Biosciences, INC. | $28.86 | 2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $23.16 | 2024 | Xelstrym |
| Collegium Pharmaceutical, INC. | $18.00 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Geraldei Paul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.